Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All metformin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMetforminMetformin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 15% Improvement Relative Risk Metformin for COVID-19  Alieva et al.  Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 763 patients in Uzbekistan (April - December 2020) Lower hospitalization with metformin (not stat. sig., p=0.56) c19early.org Alieva et al., Obesity and metabolism, Jun 2023 Favors metformin Favors control

Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study

Alieva et al., Obesity and metabolism, doi:10.14341/omet12801
Jun 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Metformin for COVID-19
3rd treatment shown to reduce risk in July 2020
 
*, now known with p < 0.00000000001 from 87 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 763 COVID-19 patients with type 2 diabetes in Uzbekistan, showing lower hospitalization with metformin use in unadjusted results, without statistical significance.
Although the 15% lower hospitalization is not statistically significant, it is consistent with the significant 18% lower hospitalization [11‑24%] from meta analysis of the 23 hospitalization results to date.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of hospitalization, 15.3% lower, OR 0.85, p = 0.56, treatment 375, control 388, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alieva et al., 6 Jun 2023, retrospective, Uzbekistan, peer-reviewed, 9 authors, study period April 2020 - December 2020.
This PaperMetforminAll
Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study
Anna V Alieva, Abdulaziz A Djalilov, Feruza A Khaydarova, Anvar V Alimov, Dilovar Z Khalilova, Vasila A Talenova, Nasiba U Alimova, Malika D Aripova, Akida S Sadikova
Obesity and metabolism, doi:10.14341/omet12801
Tashkent city health department, Uzbekistan BACKGROUND: Since the very first outbreak, scientists have been trying to determine the most critical pathogenetic mechanisms for the development of COVID-19 and related complications, analyze individual subpopulations of patients with chronic diseases and develop optimal tactics to combat not only the infection itself but also its acute and chronic complications. AIM: to assess the COVID-19 course among patients with Type 1 and Type 2 DM. MATERIALS AND METHODS: A retrospective cohort study of Tashkent inhabitants, who had COVID-19 from April to December 2020, was performed. The data were obtained from the single electronic database of registered cases of COVID-19. All data were analyzed using a logistic regression in STATA 17.0 software. Further, the matched case-control study was performed for patients with type 2 DM and no DM based on age, gender, and BMI. RESULTS: Of the 5023 analyzed subjects, 72.63% had no diabetes mellitus (DM), 4.24% had type 1 DM, 15.19% had type 2 DM, and 7.94% was diagnosed with DM during the COVID-19 infection. DM, overweight, and obesity were associated with severe COVID-19; the most significant risk of a severe course was found in persons with type 2 DM. The risk of a lethal outcome and the need for prescription of glucocorticoids did not show a significant association with diabetes in Tashkent. The clinical features of COVID-19 were more common in patients with type 2 DM, especially for shortness of breath, chest pain, and arrhythmia. The persons receiving SU have complained of dyspnea significantly more often than matched patients without DM. Metformin and DPP4i were the groups of drugs that were not associated with significantly increased risk of hospitalization of patients because of COVID-19. The matched case-control study did not reveal statistically significant differences in the disease course severity, need for hospitalization and glucocorticoids, and death depending on the glucose-lowering therapy preceding the onset of COVID-19. CONCLUSION: Diabetes, age and overweight/obesity were associated with severe course of COVID-19 in Tashkent. There was no statistical difference in COVID-19 severity depending on initial glucose-lowering therapy.
ADDITIONAL INFORMATION Funding. This study was funded by the grant by the Ministry of Innovation of the Republic of Uzbekistan A-CC-2021-139. Conflict of interest
References
Abu-Jamous, Anisimovich, Baxter, Associations of comorbidities and medications with COVID-19 outcome: a retrospective analysis of real-world evidence data. medRxiv, doi:10.1101/2020.08.20.20174169
Alieva, Djalilov, Khaydarova, Alimov, Khalilova et al., Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study, Obesity and metabolism
Alieva, Ismailov, Rahimova, Epidemiology of diabetes and prediabetes in Uzbekistan: Screening results, Health Sci J, doi:10.21767/1791-809X.1000609
Barron, Bakhai, Kar, Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a wholepopulation study, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30272-2
Bornstein, Rubino, Khunti, Practical recommendations for the management of diabetes in patients with COVID-19, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30152-2
Bramante, Ingraham, Murray, Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis, Lancet Heal Longev, doi:10.1016/S2666-7568(20)30033-7
Cameron, Morrison, Levin, Anti-Inflammatory effects of metformin irrespective of diabetes status, Circ Res, doi:10.1161/CIRCRESAHA.116.308445
Cariou, Hadjadj, Wargny, Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study, Diabetologia, doi:10.1007/s00125-020-05180-x
Casqueiro, Casqueiro, Alves, Infections in patients with diabetes mellitus: A review of pathogenesis, Indian J Endocrinol Metabol, doi:10.4103/2230-8210.94253
Chen, Yang, Cheng, Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, Diabetes Care, doi:10.2337/dc20-0660
Cheng, Liu, Li, Metformin is associated with higher incidence of acidosis, but not mortality, in Individuals with COVID-19 and Pre-existing type 2 diabetes, Cell Metab, doi:10.1016/j.cmet.2020.08.013
Crouse, Grimes, Li, Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes, Front Endocrinol (Lausanne), doi:10.3389/fendo.2020.600439
Dalan, Ang, Tan, The association of Hypertension and Diabetes Pharmacotherapy with COVID-19 severity and immune signatures: an observational study, Eur Heart J Cardiovasc Pharmacother, doi:10.1093/ehjcvp/pvaa098.pvaa098
Fadini, Morieri, Longato, Exposure to dipeptidylpeptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study, Diabetes, Obes Metab, doi:10.1111/dom.14097
Gao, Liu, Zhong, Risk of metformin in type 2 diabetes patients with COVID-19: a preliminary retrospective report, Clin Transl Sci, doi:10.1111/cts.12897
Grant, The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects, Diabete metab
Guan, Liang, Zhao, Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis, Eur Respir J
Guo, Li, Dong, Diabetes is a risk factor for the progression and prognosis of COVID-19, Diabetes Metab Res Rev, doi:10.1002/dmrr.3319
Gupta, Ghosh, Singh, Misra, Clinical considerations for patients with diabetes in times of COVID-19 epidemic, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.03.002
Ho, Huang, Tsai, Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease, Respir Res, doi:10.1186/s12931-019-1035-9
Holman, Knighton, Kar, Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30271-0
Hughes, Smith-Mccain, Effects of sulfonylurea compounds on pneumocystis carinii, J Infect Dis, doi:10.1093/infdis/153.5.944
Izzi-Engbeaya, Distaso, Amin, Severe COVID-19 and diabetes e a retrospective cohort study from three London 2 teaching hospitals. medRxiv, doi:10.1101/2020.08.07.20160275
Jiang, Chen, Liu, Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study, Diabetes Res Clin Pract, doi:10.1016/j.diabres.2020.108619
Kim, Jeon, Kim, The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea, Diabetes Metab J, doi:10.4093/dmj.2020.0146
Li, Wei, Li, Metformin use in diabetes prior to hospitalization: Effects on mortality in Covid-19, Endocr Pract, doi:10.4158/EP-2020-0466
Liang, Ding, Li, Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies, Crit Care, doi:10.1186/s13054-019-2346-4
Luo, Qiu, Liu, Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am J Trop Med Hyg, doi:10.4269/ajtmh.20-0375
Mendy, Gopal, Alcorn, Forno, Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin, Respirology, doi:10.1111/resp.13486
Orcid, -mail: endocrin@uzsci.net Халилова Диловар Захириддиновна, Dilovar Z. Khalilova
Orcid, None
Orcid, alimovna@mail.ru Алимов Анвар Валиевич, д.м.н., профессор [Anvar V
Peleg, Weerarathna, Mccarthy, Davis, Common infections in diabetes: pathogenesis, management and relationship to glycaemic control, Diabetes Metab Res Rev, doi:10.1002/dmrr.682
Philipose, Smati, Wong, Obesity, old age, and frailty are the true risk factors for COVID-19 mortality and not chronic disease or ethnicity. medRxiv, doi:10.1101/2020.08.12.20156257
Raj, Mou, Smits, Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC, Nature, doi:10.1038/nature12005
Sinclair, Dhatariya, Burr, Guidelines for the management of diabetes in care homes during the Covid-19 pandemic, Diabet Med, doi:10.1111/dme.14317
Singh, Gupta, Ghosh, Misra, Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations, Diabetes Metab Synd, doi:10.1016/j.dsx.2020.04.004
Singh, Khunti, Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: a narrative review, Diabetes Res Clin Pract, doi:10.1016/j.diabres.2020.108266
Singh, Singh, Saboo, Misra, Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A critical appraisal of literature, Diabetes Metab Syndr Clin Res Rev, doi:10.1016/j.dsx.2020.12.026
Tsoyi, Jang, Nizamutdinova, Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice, Br J Pharmacol, doi:10.1111/j.1476-5381.2010.01126.x
Wargny, Potier, Gourdy, Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study, Diabetologia, doi:10.1007/s00125-020-05351-w
Wu, Chen, Cai, Risk Factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease, JAMA Intern Med, doi:10.1001/jamainternmed.2020.0994
Xin, Wei, Ji, Metformin uniquely prevents thrombosis by inhibiting platelet activation and mtDNA release, Sci Rep, doi:10.1038/srep36222
You, Lee, Chun, Clinical outcomes of COVID-19 patients with type 2 diabetes: A populationbased study in Korea, Endocrinol Metab, doi:10.3803/EnM.2020.787
Yuan, Qi, Peng, Molecular basis of binding between Middle East Respiratory Syndrome Coronavirus and CD26 from seven bat species, J Virol, doi:10.1128/JVI.01387-19
Zhang, He, Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis, Eur J Clin Pharmacol, doi:10.1007/s00228-019-02786-y
Акида Саттаровна, Phd, Akida, Sadikova, Phd et al., -mail: akidahon@yandex.ru *Автор, ответственный за переписку / Corresponding author, doi:10.14341/omet12801TOCITETHISARTICLE
Алиева, Валерьевна, Anna, Alieva, Md, адрес: Республика Узбекистан, 100125, Ташкент, ул. Мирзо Улугбека, д. 56 [address: 56, M. Ulugbek str
Информация Об Авторах, None
Малика Дильшадовна, Md [malika, Aripova, Orcid, None
Насиба, None, PhD [Nasiba U. Alimova, PhD
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit